The Many Faces of Cytokine Release Syndrome-Related Coagulopathy

Area of Science:

• Hematology
• Immunology
• Critical Care Medicine

Background:

• Cytokine release syndrome (CRS) is increasingly recognized in conditions like COVID-19.
• CRS is linked to systemic inflammation and hematological complications, notably coagulopathy.
• Coagulopathy affects endothelial cells, platelets, coagulation cascade, and fibrinolytic system.

Purpose of the Study:

• To analyze the diverse presentations of coagulopathy in different CRS etiologies.
• To compare the specific hemostatic abnormalities associated with primary HLH, CAR T-cell therapy, and COVID-19.
• To highlight microvascular thrombosis as a common pathological feature across various CRS causes.

Main Methods:

• Review of clinical data and literature on CRS and associated coagulopathies.
• Comparative analysis of cytokine profiles and hemostatic derangements in distinct CRS conditions.
• Examination of pathological findings, particularly microvascular thrombosis.

Main Results:

• Primary HLH exhibits severe consumptive coagulopathy with high bleeding risk.
• CAR T-cell therapy is associated with mild consumptive coagulopathy and thrombotic risk.
• COVID-19-related CRS shows rare consumptive coagulopathy but significant thrombotic risk.
• Differences in coagulopathy are attributed to CRS severity and underlying conditions.

Conclusions:

• CRS-induced coagulopathy varies significantly based on the underlying cause.
• Understanding these differences is crucial for managing bleeding and thrombotic risks.
• Investigational therapies targeting cytokine pathways aim to mitigate CRS-related coagulopathy.